Sienna Biopharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Out of Business

Sienna Biopharmaceuticals General Information

Description

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Contact Information

Formerly Known As
Sienna Labs, Sienna Labs, Inc.
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 30699 Russell Ranch Road
  • Suite 140
  • Westlake Village, CA 91362
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Corporate Office
  • 30699 Russell Ranch Road
  • Suite 140
  • Westlake Village, CA 91362
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sienna Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Out of Business 10-Dec-2019 Completed Out of Business
6. Bankruptcy: Admin/Reorg 17-Sep-2019 Completed Bankruptcy: Admin/Reorg
5. IPO 27-Jul-2017 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 15-May-2017 Completed Clinical Trials - General
3. Later Stage VC (Series A3) 18-Jul-2016 Completed Clinical Trials - General
2. Early Stage VC (Series B) 20-Jun-2013 $1.5M $1.85M Completed Startup
1. Early Stage VC (Series A) 05-Feb-2013 $350K $350K Completed Startup
To view Sienna Biopharmaceuticals’s complete valuation and funding history, request access »

Sienna Biopharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A3
Series A2 6,466,287 $0.000100 $0.23 $0.23 1x $0.23 6.72%
Series A1 2,189,334 $0.000100 $0.15 $0.15 1x $0.15 2.28%
To view Sienna Biopharmaceuticals’s complete cap table history, request access »

Sienna Biopharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechno
Pharmaceuticals
Westlake Village, CA
39 As of 2019

Nashville, TN
 

Alameda, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sienna Biopharmaceuticals Competitors (2)

One of Sienna Biopharmaceuticals’s 2 competitors is Harrow, a Corporation company based in Nashville, TN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harrow Corporation Nashville, TN
Exelixis Formerly VC-backed Alameda, CA
You’re viewing 2 of 2 competitors. Get the full list »

Sienna Biopharmaceuticals Patents

Sienna Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2020023389-A1 Reduced exposure compositions modulating therapeutic targets Inactive 23-Jul-2018
WO-2020023387-A1 Uses of polymer conjugates of indolocarbazole compounds with reduced exposure Inactive 23-Jul-2018
WO-2019143971-A2 Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure Inactive 18-Jan-2018
WO-2019143971-A3 Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure Inactive 18-Jan-2018
WO-2019126270-A1 Formulations for dermal delivery of polymer conjugates of indolocarbazole compounds with reduced exposure Inactive 20-Dec-2017 A61P1/00
To view Sienna Biopharmaceuticals’s complete patent history, request access »

Sienna Biopharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sienna Biopharmaceuticals Acquisitions (1)

Sienna Biopharmaceuticals’s most recent deal was a Merger/Acquisition with Creabilis for . The deal was made on 06-Dec-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Creabilis 06-Dec-2016 Merger/Acquisition Drug Discovery
To view Sienna Biopharmaceuticals’s complete acquisitions history, request access »

Sienna Biopharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Sienna Biopharmaceuticals’s complete esg history, request access »

Sienna Biopharmaceuticals FAQs

  • When was Sienna Biopharmaceuticals founded?

    Sienna Biopharmaceuticals was founded in 2010.

  • Where is Sienna Biopharmaceuticals headquartered?

    Sienna Biopharmaceuticals is headquartered in Westlake Village, CA.

  • What is the size of Sienna Biopharmaceuticals?

    Sienna Biopharmaceuticals has 39 total employees.

  • What industry is Sienna Biopharmaceuticals in?

    Sienna Biopharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Sienna Biopharmaceuticals a private or public company?

    Sienna Biopharmaceuticals is a Private company.

  • What is Sienna Biopharmaceuticals’s current revenue?

    The current revenue for Sienna Biopharmaceuticals is .

  • How much funding has Sienna Biopharmaceuticals raised over time?

    Sienna Biopharmaceuticals has raised $154M.

  • Who are Sienna Biopharmaceuticals’s competitors?

    Harrow and Exelixis are competitors of Sienna Biopharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process